6,586
Views
11
CrossRef citations to date
0
Altmetric
Editorial

Will delayed release metformin provide better management of diabetes type 2?

Pages 627-630 | Received 04 Jan 2016, Accepted 27 Jan 2016, Published online: 19 Feb 2016

Figures & data

Figure 1. Characteristics of the different formulations of metformin: delayed release compared with extended release and immediate release. GI: gastrointestinal; GLP-1: glucagon-like peptide-1; BID: twice a day; TID: three times a day.

Figure 1. Characteristics of the different formulations of metformin: delayed release compared with extended release and immediate release. GI: gastrointestinal; GLP-1: glucagon-like peptide-1; BID: twice a day; TID: three times a day.

Table 1. Main results (changes from baseline) of a 12-week, phase 2, placebo-controlled, dose-ranging study comparing metformin DR 600, 800, or 1,000 mg administered once daily; blinded placebo; or unblinded metformin XR 1,000 or 2,000 mg once-daily (reference) in patients with T2D (drug-naïve or after a 14–17 day wash-out) and an estimated glomerular filtration rate 60 ml/min/1.73 m2. Adapted from data reported in reference.[Citation13]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.